Clinical Trial Update: Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the long-term efficacy of faricimab using a treat-and-extend regimen for Type 3 macular neovascularization associated with age-related …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• VABYSMO (faricimab)

Snippet

Sponsor: Kim's Eye Hospital | Conditions: Age-related Macular Degeneration (ARMD), Choroidal Neovascularization | Phase 4 | Status: NOT_YET_RECRUITING